Management of Recurrent Nodal Marginal Zone Lymphoma

Recurrent nodal marginal zone lymphoma presents across a clinical spectrum — from indolent, asymptomatic relapse to clinically aggressive disease. The appropriate management pathway depends on symptom burden, extent of relapse, and response to prior treatment.

Clinical Scenario

This protocol covers patients with nodal marginal zone lymphoma in the recurrent disease setting. Individualised decision-making is required, taking into account whether the relapse is localised or systemic, and how durable the prior remission was.

Treatment Approach (Partial Overview)

Asymptomatic patients may be managed with careful observation, while those requiring systemic intervention have evidence-based options — including chemoimmunotherapy and targeted agents — whose selection depends on specific clinical criteria detailed in the full protocol.

The complete regimen selection algorithm, indications, and sequencing criteria are available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2019.10.010

Asymptomatic patients may be observed (watch-and-wait) and RT may be considered for MZL patients with localised relapses.
If systemic treatment is required, chemoimmunotherapy can be repeated after long initial remissions (24 months).
Thus, these targeted agents may become a treatment option, in particular for patients with short remissions after rituximab-containing chemoimmunotherapy [III, B].

View source ↗